Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cell surface receptors and associated glycoproteins represent a broad and heterogeneous category of proteins and conjugated carbohydrates expressed on the plasma membrane of malignant cells. These molecules serve critical roles in the oncogenic process, including the mediation of growth factor signaling, cell-to-cell adhesion, and the modulation of the tumor microenvironment to facilitate immune evasion. While many of these proteins are also found on normal cells, they are often overexpressed, mutated, or aberrantly glycosylated in cancer, making them primary targets for therapeutic intervention. Common examples within this category include the epidermal growth factor receptor (EGFR) family, various mucins like MUC1, and specific glycoproteins such as TAG-72. Because this term describes a diverse class of molecules rather than a single biological entity, it is generally considered a functional grouping used in oncology research rather than a specific therapeutic target.
Various mechanisms including signal inhibition, antibody-dependent cellular cytotoxicity (ADCC), and drug delivery via conjugation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor cell surface receptors and associated glycoproteins.